glp-1 amgen A GIPR antagonist conjugated to analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings MariTide: What to know about

Assessing the Oncological Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis

Caloric floor maintenance Set a hard floor for daily caloric intake and do not go below it, regardless of how little your appetite demands

Employers should keep in mind that indication-based coverage decisions (such as covering GLP-1 drugs for diabetes treatment but not for treatment of obesity or other conditions, such as addiction) can potentially raise concerns under the Americans with Disabilities Act (ADA), the ACA, HIPAAs nondiscrimination requirements, or the Mental Health Parity and Addiction Equity Act, among other laws

doi: 10.1016/j.biopsych.2026.05.002 10.1016/j.biopsych.2026.05.002